Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Mar. 25, 2016

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	March 25, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.2	$	24.4	$	9.8	$	—
Foreign exchange forward and option contracts	1.9		1.9		—		—
	$	36.1	$	26.3	$	9.8	$	—

Liabilities:
Deferred compensation liabilities	$	22.1	$	—	$	22.1	$	—
Contingent consideration and acquired contingent liabilities	204.2		—		—		204.2
	$	226.3	$	—	$	22.1	$	204.2



	September 25, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.6	$	24.2	$	10.4	$	—
	$	34.6	$	24.2	$	10.4	$	—

Liabilities:
Deferred compensation liabilities	$	20.0	$	—	$	20.0	$	—
Contingent consideration and acquired contingent liabilities	174.6		—		—		174.6
Foreign exchange forward and option contracts	3.3		3.3		—		—
	$	197.9	$	3.3	$	20.0	$	174.6

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities



Balance at September 25, 2015	$	174.6
Acquisition date fair value of contingent consideration	52.0
Acquisition date fair value of acquired contingent consideration	10.6
Payments	(30.0		)
Accretion expense	3.3
Fair value adjustment	(6.3		)
Balance at March 25, 2016	$	204.2

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	March 25, 2016				September 25, 2015
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable-rate receivable securitization	$	215.0	$	215.0	$	153.0	$	153.0
3.50% notes due April 2018	300.0		286.4		300.0		294.3
4.875% notes due April 2020	700.0		654.3		700.0		684.1
Term loans due March 2021	1,968.5		1,914.6		1,978.5		1,966.5
4.00% term loan due February 2022	6.4		6.4		7.9		7.9
9.50% debentures due May 2022	10.4		11.4		10.4		13.0
5.75% notes due August 2022	884.0		812.9		900.0		876.1
8.00% debentures due March 2023	4.4		4.6		4.4		5.3
4.75% notes due April 2023	600.0		499.2		600.0		539.6
5.625% notes due October 2023	740.0		671.3		750.0		705.2
5.50% notes due April 2025	700.0		621.4		700.0		646.0
Revolving credit facility	400.0		400.0		500.0		500.0

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	March 25, 2016		March 27, 2015		March 25, 2016		March 27, 2015
CuraScript, Inc.	30	%	28	%	31	%	31	%
McKesson Corporation	12	%	21	%	13	%	19	%
Cardinal Health, Inc.	10	%	14	%	9	%	14	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	March 25, 2016		September 25, 2015
McKesson Corporation	25	%	24	%
CuraScript, Inc.	13	%	16	%
Cardinal Health, Inc.	13	%	13	%
Amerisource Bergen Corporation	11	%	12	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	March 25, 2016		March 27, 2015		March 25, 2016		March 27, 2015
Acthar	27	%	28	%	29	%	31	%
Inomax	13	%	—	%	12	%	—	%